Completed OBSERVATIONAL NCT04975971

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery

Sponsor: Nicole Fram M.D.

Conditions Anterior Chamber Inflammation Cataract Senile Corneal Defect Corneal Edema Cortical Cataract Nuclear Cataract Ocular Pain Penetrating KeratoPlasty

Interventions Dextenza 0.4Mg Ophthalmic Insert

Updated 3 times since 2021 Last updated: Jul 14, 2021 Started: Mar 9, 2021 Primary completion: May 19, 2021 Completion: May 19, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Anterior Chamber Inflammation and Cataract Senile and is currently completed. Nicole Fram M.D. leads this study, which shows 3 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Sep 2021 — Jul 2024 [monthly]

Completed

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nicole Fram M.D.

Data source: Advanced Vision Care

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States